drugset / Trial / NCT07706088
Effect of Tirzepatide on Diabetic Peripheral Sensorimotor Neuropathy
Phase 4
Not yet recruiting
40 enrolled
Post Graduate Institute of Medical Education and Research, Chandigarh
RandomizedParallel-groupOpen-labelTreatment
Summary
Tirzepatide is a dual agonist of GLP-1 Receptor and the GIP receptor, producing substantial improvement in glycaemic control, weight reduction and insulin sensitivity. Beyond its metabolic effects, incretin signalling has demonstrated neuroprotective and neurotropic properties, including activation of intracellular pathways that enhance neuronal survival and regeneration. Using tirzapatide for diabetic sensorimotor peripheral neuropathy and assessing with CCM / NCS and BDNF will represent three complementary aspects of nerve regeneration: metabolic control, structural nerve repair and neurotrophic signalling.
Timeline
- Start
- 2026-07
- Primary completion
- 2028-07-01
- Completion
- 2028-07-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Tirzepatide | Peptide | 7.5 mg | — |